Back

Expression of C5aR1 in Cutaneous Squamous Cell Carcinoma is Associated with Invasion, Metastasis and Poor Prognosis

Heiskanen, L.; Nissinen, L.; Siljamaki, E.; Knuutila, J.; Pellinen, T.; Kallajoki, M.; Heino, J.; Riihila, P.; Kahari, V.-M.

2024-08-19 dermatology
10.1101/2024.08.16.24312116 medRxiv
Show abstract

Cutaneous squamous cell carcinoma (cSCC) is the most common metastatic skin cancer, and the metastatic disease is associated with poor prognosis. We have examined the role of complement C5a receptor, C5aR1, in the progression and metastasis of cSCC. C5aR1 expression was increased in cSCC cells in 3D spheroid co-culture model in the presence of fibroblasts, and that treatment with recombinant C5a enhanced the invasion of cSCC cells. Staining for C5aR1 was detected on the surface of tumor cells at the invasive edge of human cSCC xenografts in vivo. Staining of metastatic and non-metastatic primary human cSCCs, premalignant and benign epidermal lesions and normal skin for C5aR1 with multiplex immunofluorescence and chromogenic immunohistochemistry revealed increased expression of C5aR1 on the surface of tumor cells and fibroblasts in invasive cSCCs and recessive dystrophic epidermolysis bullosa-associated cSCCs compared to cSCC in situ, actinic keratoses, seborrheic keratoses and normal skin. Increased expression of C5aR1 on the tumor cell surface and in fibroblasts was associated with metastatic risk and poor disease-specific survival of patients with primary cSCC. These findings reveal the role of C5aR1 in cSCC invasion and identify C5aR1 as a novel biomarker for metastasis risk and poor prognosis in patients with cSCC. The results also suggest that C5aR1 could be a novel therapeutic target for treatment of locally advanced and metastatic cSCC.

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

1
Experimental Dermatology
10 papers in training set
Top 0.1%
14.7%
2
Journal of Investigative Dermatology
49 papers in training set
Top 0.1%
11.8%
3
Pigment Cell & Melanoma Research
11 papers in training set
Top 0.1%
9.6%
4
Experimental & Molecular Medicine
14 papers in training set
Top 0.1%
5.5%
5
Theranostics
37 papers in training set
Top 0.1%
4.8%
6
Scientific Reports
3612 papers in training set
Top 27%
4.0%
50% of probability mass above
7
JID Innovations
11 papers in training set
Top 0.1%
3.2%
8
Heliyon
152 papers in training set
Top 1%
3.2%
9
Matrix Biology
29 papers in training set
Top 0.1%
3.2%
10
Blood Advances
62 papers in training set
Top 0.5%
3.2%
11
British Journal of Dermatology
11 papers in training set
Top 0.1%
2.7%
12
eLife
5828 papers in training set
Top 39%
2.6%
13
Annals of Oncology
14 papers in training set
Top 0.1%
2.4%
14
Human Genomics
21 papers in training set
Top 0.1%
2.1%
15
European Journal of Cancer
11 papers in training set
Top 0.1%
2.1%
16
PLOS ONE
5266 papers in training set
Top 56%
1.1%
17
Allergy
25 papers in training set
Top 0.3%
1.1%
18
Frontiers in Oncology
103 papers in training set
Top 3%
1.1%
19
Frontiers in Immunology
638 papers in training set
Top 8%
1.1%
20
The Journal of Pathology
26 papers in training set
Top 0.7%
0.9%
21
Cell Communication and Signaling
51 papers in training set
Top 1%
0.8%
22
Cell & Bioscience
14 papers in training set
Top 0.1%
0.8%
23
JCI Insight
277 papers in training set
Top 8%
0.8%
24
Frontiers in Medicine
120 papers in training set
Top 4%
0.8%
25
BMC Cancer
67 papers in training set
Top 2%
0.8%
26
Cancer Research
130 papers in training set
Top 3%
0.8%
27
Journal for ImmunoTherapy of Cancer
75 papers in training set
Top 2%
0.8%
28
Cancer Research Communications
51 papers in training set
Top 2%
0.8%
29
Stem Cell Research & Therapy
30 papers in training set
Top 0.7%
0.8%
30
npj Precision Oncology
53 papers in training set
Top 2%
0.6%